Instinet started coverage on shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in a research report issued to clients and investors on Friday, Marketbeat reports. The brokerage set a “reduce” rating on the biopharmaceutical company’s stock.

ALNY has been the subject of several other reports. Chardan Capital set a $110.00 target price on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, June 12th. ValuEngine upgraded shares of Alnylam Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, June 13th. Ladenburg Thalmann Financial Services set a $90.00 target price on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, July 17th. BidaskClub upgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 5th. Finally, J P Morgan Chase & Co restated a “hold” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, June 26th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $82.25.

Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 2.48% on Friday, reaching $76.21. 1,348,848 shares of the company traded hands. The stock’s market capitalization is $6.99 billion. The stock’s 50-day moving average is $81.65 and its 200-day moving average is $68.34. Alnylam Pharmaceuticals has a 1-year low of $31.38 and a 1-year high of $89.45.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the consensus estimate of ($1.22) by ($0.12). The company had revenue of $15.93 million for the quarter, compared to analysts’ expectations of $23.86 million. Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The firm’s revenue for the quarter was up 82.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.05) earnings per share. Equities research analysts expect that Alnylam Pharmaceuticals will post ($5.18) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/15/alnylam-pharmaceuticals-inc-alny-research-coverage-started-at-instinet.html.

Large investors have recently modified their holdings of the stock. Pacer Advisors Inc. boosted its position in shares of Alnylam Pharmaceuticals by 22.0% during the second quarter. Pacer Advisors Inc. now owns 11,610 shares of the biopharmaceutical company’s stock worth $926,000 after acquiring an additional 2,093 shares during the last quarter. TLP Group LLC bought a new position in shares of Alnylam Pharmaceuticals during the first quarter worth $380,000. Wellington Management Group LLP boosted its position in shares of Alnylam Pharmaceuticals by 0.3% during the first quarter. Wellington Management Group LLP now owns 12,041,179 shares of the biopharmaceutical company’s stock worth $617,111,000 after acquiring an additional 31,208 shares during the last quarter. BB Biotech AG boosted its position in shares of Alnylam Pharmaceuticals by 4.2% during the first quarter. BB Biotech AG now owns 1,241,338 shares of the biopharmaceutical company’s stock worth $63,619,000 after acquiring an additional 50,000 shares during the last quarter. Finally, Hemenway Trust Co LLC bought a new position in shares of Alnylam Pharmaceuticals during the second quarter worth $235,000. Hedge funds and other institutional investors own 94.27% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.